These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. MacInnes A, Fairman DA, Binding P, Rhodes Ja, Wyatt MJ, Phelan A, Haddock PS, Karran EH. Circ Res; 2003 Aug 08; 93(3):e26-32. PubMed ID: 12869391 [Abstract] [Full Text] [Related]
23. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease]. Fedorova TA, Il'ina IuV, Sotnikova TI, Rybakova MK. Klin Med (Mosk); 2004 Aug 08; 82(11):15-20. PubMed ID: 15656392 [Abstract] [Full Text] [Related]
24. [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy]. Sisakian AS, Torgomian AL, Barkhudarian AL. Klin Med (Mosk); 2006 Aug 08; 84(10):55-8. PubMed ID: 17201276 [Abstract] [Full Text] [Related]
27. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, Abbate A, Vrtovec B, Khan BV, Vetrovec GW. Am J Cardiol; 2009 Dec 15; 104(12):1708-16. PubMed ID: 19962481 [Abstract] [Full Text] [Related]
28. Clinical benefits of trimetazidine in patients with recurrent angina. Szwed H. Coron Artery Dis; 2004 May 15; 15 Suppl 1():S17-21. PubMed ID: 15179124 [Abstract] [Full Text] [Related]
30. Metabolic modulation: a new therapeutic target in treatment of heart failure. Palaniswamy C, Mellana WM, Selvaraj DR, Mohan D. Am J Ther; 2011 Nov 15; 18(6):e197-201. PubMed ID: 20393344 [Abstract] [Full Text] [Related]
31. [Possibilities of myocardial cytoprotection in complex treatment of patients with chronic heart failure]. Vasiuk IuA, Iushchuk EN, Shkol'nik EL, Khadzegova AB, Vit'ko NK, Vakhromeeva MN. Kardiologiia; 2006 Nov 15; 46(11):48-56. PubMed ID: 17159882 [Abstract] [Full Text] [Related]
33. Enalapril for severe congestive heart failure. A double-blind study. Jennings G, Kiat H, Nelson L, Kelly MJ, Kalff V, Johns J. Med J Aust; 1984 Nov 24; 141(11):723-6. PubMed ID: 6094995 [Abstract] [Full Text] [Related]
34. [Effect of acetyl-CoA C-acyltransferase inhibitor trimetazidine on parameters of global and local systolic and diastolic functions of left ventricular myocardium in patients with combined postinfarction ischemic syndrome]. Kastanaian AA, Nelasov NIu, Eroshenko OL, Kazarian NB, Drobotia NV. Kardiologiia; 2003 Nov 24; 43(9):21-7. PubMed ID: 14593366 [Abstract] [Full Text] [Related]
35. The effect of trimetazidine added to pharmacological treatment on all-cause mortality in patients with systolic heart failure. Grajek S, Michalak M. Cardiology; 2015 Nov 24; 131(1):22-9. PubMed ID: 25832112 [Abstract] [Full Text] [Related]
37. [Plasma hemostasis and biochemical indices in trimetazidine treatment of patients with chronic heart failure]. Tereshchenko SN, Drozdov VN, Levchuk NN, Demidova IV. Ter Arkh; 1998 Oct 24; 70(6):41-4. PubMed ID: 9695225 [Abstract] [Full Text] [Related]
38. [Trimetazidine in the Treatment of Chronic HeartFailure]. Zhirov IV, Osmolovskaya YF, Tereshchenko SN. Kardiologiia; 2016 Jan 24; 56(1):79-85. PubMed ID: 28294737 [Abstract] [Full Text] [Related]
39. Clinical use of beta-blockers in patients with heart failure. Eichhorn EJ. J Card Fail; 2000 Jun 24; 6(2 Suppl 1):40-6. PubMed ID: 10908097 [Abstract] [Full Text] [Related]
40. Effect of trimetazidine on the functional capacity of ischemic heart disease patients not suitable for revascularization: Meta-analysis of randomized controlled trials. Ajabnoor A, Mukhtar A. PLoS One; 2022 Jun 24; 17(2):e0263932. PubMed ID: 35148340 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]